Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


15. January 2020 | 07:42 CET

Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?

  • Medical

Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.

time to read: 1 minutes by Mario Hose


 

All analysts convinced of growth course

All analysts - including Commerzbank and Bankhaus Metzler - are convinced that M1 Kliniken will continue to grow at double-digit rates in the coming years and recommend the share as a buy. Five analysts expect M1 Kliniken to break through the EUR 100 million revenue barrier this year (2018: EUR 65 million). The average expectation for net income in 2020 is EUR 9.8 million (2018: EUR 6.6 million).

Sales and profit growth foreseeable

M1 has already laid the foundation for further revenue and profit growth in the current year. In 2019, 12 new specialist centres were opened, significantly more than in previous years (average 6 p.a.). This means that the Group now operates 36 outpatient centres for aesthetic medicine. With Dortmund, Bielefeld, Rostock, Stuttgart II and Frankfurt (M1 Dental), M1 has increased the number of locations in Germany by 5 to 28.

In addition, larger premises were moved into Hamburg and Hanover. At the same time, M1 is specifically increasing the range of treatments offered in the existing specialist centres. For example, aesthetic laser treatments, such as hair removal, are now offered at 20 beauty locations under the "M1 Laser" brand.

Internationalization as growth driver

International expansion was added as an additional growth driver last year. After the first international "M1 Med Beauty" specialist centre for aesthetic medicine was opened in Vienna in December 2018, 7 foreign locations have been added in recent months. In addition to a further location in Austria (Linz), the company has successfully entered the markets in the Netherlands (Amsterdam, Rotterdam), Switzerland (Zurich) and Australia (Melbourne, Sydney, Brisbane).

Project pipeline gives reason to expect dynamic start to 2020

In addition, the project development for 10 further specialist centres - 5 of them in Great Britain alone - has been largely completed. The M1 Group is thus fully on track to achieve its goal: 50 specialist beauty centres by the end of 2020. M1 has already secured the necessary financing in September 2018 through a capital increase.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

05. May 2020 | 08:33 CET

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

Read

24. April 2020 | 07:36 CET

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

Read

04. March 2020 | 07:27 CET

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

Read